Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer

References

• Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al. Bone marrow and the control of immunity. Cell Mol Immunol 2011; In press http://dx.doi.org/10.1038/cmi.2011.47; PMID: 22020068
   PubMed Web of Science ®Google Scholar
• Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8:363 - 72; http://dx.doi.org/10.1016/S1074-7613(00)80541-5; PMID: 9529153
   PubMed Web of Science ®Google Scholar
• Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005; 174:1269 - 73; PMID: 15661882
   PubMed Web of Science ®Google Scholar
• Mazo IB, Honczarenko M, Leung H, Cavanagh LL, Bonasio R, Weninger W, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 2005; 22:259 - 70; http://dx.doi.org/10.1016/j.immuni.2005.01.008; PMID: 15723813
   PubMed Web of Science ®Google Scholar
• Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997; 158:3716 - 20; PMID: 9103435
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9:1151 - 7; http://dx.doi.org/10.1038/nm914; PMID: 12910264
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7:452 - 8; http://dx.doi.org/10.1038/86523; PMID: 11283672
   PubMed Web of Science ®Google Scholar
• Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001; 92:96 - 105; http://dx.doi.org/10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q; PMID: 11279612
   PubMed Web of Science ®Google Scholar
• Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64:8451 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-04-1987; PMID: 15548717
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102:5126 - 31; http://dx.doi.org/10.1073/pnas.0501701102; PMID: 15795373
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Osman K, Geller MD. . Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy. J Exp Med2003;198:1753-7.
   PubMed Web of Science ®Google Scholar
• Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160:1212 - 8; PMID: 9570536
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183 - 90; PMID: 10605010
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7:1339 - 46; http://dx.doi.org/10.1038/nm1201-1339; PMID: 11726975
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562 - 7; http://dx.doi.org/10.1038/nm863; PMID: 12704383
   PubMed Web of Science ®Google Scholar
• Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146:1727 - 36; http://dx.doi.org/10.1210/en.2004-1211; PMID: 15637291
   PubMed Web of Science ®Google Scholar
• Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003; 97:739 - 47; http://dx.doi.org/10.1002/cncr.11181; PMID: 12548571
   PubMed Web of Science ®Google Scholar
• Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13:62 - 9; http://dx.doi.org/10.1038/nm1519; PMID: 17159986
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107:1235 - 44; http://dx.doi.org/10.1172/JCI11685; PMID: 11375413
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004; 21:399 - 408; http://dx.doi.org/10.1007/s10585-005-0056-6; PMID: 15672864
   PubMed Web of Science ®Google Scholar
• Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007; 204:57 - 63; http://dx.doi.org/10.1084/jem.20061852; PMID: 17200412
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17:737 - 47; http://dx.doi.org/10.1016/S1074-7613(02)00480-6; PMID: 12479820
   PubMed Web of Science ®Google Scholar
• Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin Cancer Biol 2002; 12:25 - 31; http://dx.doi.org/10.1006/scbi.2001.0401; PMID: 11926408
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263 - 74; http://dx.doi.org/10.1038/nrc1586; PMID: 15776005
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295 - 307; http://dx.doi.org/10.1038/nri1806; PMID: 16557261
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715 - 27; http://dx.doi.org/10.1038/nri1936; PMID: 16977338
   PubMed Web of Science ®Google Scholar
• Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832 - 7; PMID: 11912162
   PubMed Web of Science ®Google Scholar
• Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20:318 - 29; http://dx.doi.org/10.1359/JBMR.041109; PMID: 15647826
   PubMed Web of Science ®Google Scholar
• Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3:687 - 94; http://dx.doi.org/10.1038/ni813; PMID: 12068293
   PubMed Web of Science ®Google Scholar
• Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196:851 - 7; http://dx.doi.org/10.1084/jem.20020190; PMID: 12235217
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665 - 74; http://dx.doi.org/10.1038/nri1435; PMID: 15343366
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, et al. Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Res 2007; 67:7487 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-07-0565; PMID: 17671219
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, et al. Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. J Immunol 2007; 179:1423 - 6; PMID: 17641006
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875 - 86; http://dx.doi.org/10.1084/jem.20030152; PMID: 14676299
   PubMed Web of Science ®Google Scholar
• Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002; 16:183 - 91; http://dx.doi.org/10.1016/S1074-7613(02)00279-0; PMID: 11869680
   PubMed Web of Science ®Google Scholar
• Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12:1372 - 9; http://dx.doi.org/10.1038/nm1518; PMID: 17143276
   PubMed Web of Science ®Google Scholar
• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24:33 - 63; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090646; PMID: 16551243
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756 - 65; http://dx.doi.org/10.1056/NEJMoa0809493; PMID: 19671655
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821 - 31; http://dx.doi.org/10.1056/NEJMoa044459; PMID: 16495394
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304 - 9; http://dx.doi.org/10.1038/46303; PMID: 10580503
   PubMed Web of Science ®Google Scholar
• Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A, et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 2007; 56:4104 - 12; http://dx.doi.org/10.1002/art.23138; PMID: 18050211
   PubMed Web of Science ®Google Scholar
• Zaiss MM, Frey B, Hess A, Zwerina J, Luther J, Nimmerjahn F, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010; 184:7238 - 46; http://dx.doi.org/10.4049/jimmunol.0903841; PMID: 20483756
   PubMed Web of Science ®Google Scholar
• McCabe NP, Madajka M, Vasanji A, Byzova TV. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition. Clin Exp Metastasis 2008; 25:581 - 90; http://dx.doi.org/10.1007/s10585-008-9175-1; PMID: 18506587
   PubMed Web of Science ®Google Scholar
• Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, et al. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res 2010; 70:5014 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-10-0100; PMID: 20501834
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942 - 9; http://dx.doi.org/10.1038/nm1093; PMID: 15322536
   PubMed Web of Science ®Google Scholar
• Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995 - 4000; http://dx.doi.org/10.1158/0008-5472.CAN-08-3804; PMID: 19383912
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871 - 81; http://dx.doi.org/10.1084/jem.20050930; PMID: 16606666
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting Edge: Induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177:40 - 4; PMID: 16785496
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995; 92:1327 - 31; http://dx.doi.org/10.1073/pnas.92.5.1327; PMID: 7877976
   PubMed Web of Science ®Google Scholar
• Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788 - 99; http://dx.doi.org/10.1158/0008-5472.CAN-10-1736; PMID: 20924102
   PubMed Web of Science ®Google Scholar